O	0	8	Cosmesis
O	9	12	and
O	13	19	Breast
O	19	20	-
O	20	27	Related
O	28	35	Quality
O	36	38	of
O	39	43	Life
O	44	52	Outcomes
O	53	58	After
B-intervention	59	73	Intraoperative
I-intervention	74	83	Radiation
I-intervention	84	91	Therapy
O	92	95	for
O	96	101	Early
O	102	108	Breast
O	109	115	Cancer
O	115	116	:
O	117	118	A
O	119	127	Substudy
O	128	130	of
O	131	134	the
O	135	141	TARGIT
O	141	142	-
O	142	143	A
O	144	149	Trial
O	149	150	.

O	151	153	To
O	154	160	report
O	161	164	the
O	165	170	first
O	171	184	comprehensive
O	185	198	investigation
O	199	201	of
O	202	209	patient
O	209	210	-
O	210	218	reported
O	219	227	cosmesis
O	228	231	and
O	232	238	breast
O	238	239	-
O	239	246	related
O	247	254	quality
O	255	257	of
O	258	262	life
O	263	264	(
O	264	267	QOL
O	267	268	)
O	269	277	outcomes
O	278	287	comparing
O	288	296	patients
O	297	307	randomized
O	308	310	to
O	311	315	risk
O	315	316	-
O	316	323	adapted
O	324	330	single
O	330	331	-
O	331	335	dose
O	336	350	intraoperative
O	351	360	radiation
O	361	368	therapy
O	369	370	(
O	370	376	TARGIT
O	376	377	-
O	377	381	IORT
O	381	382	)
O	383	389	versus
B-control	390	398	external
I-control	399	403	beam
I-control	404	413	radiation
I-control	414	421	therapy
I-control	422	423	(
I-control	423	427	EBRT
I-control	427	428	)
O	429	431	on
O	432	435	the
O	436	442	TARGIT
O	442	443	-
O	443	444	A
O	445	450	trial
O	450	451	.

O	452	464	Longitudinal
O	465	473	cosmesis
O	474	477	and
O	478	481	QOL
O	482	486	data
O	487	491	were
O	492	501	collected
O	502	506	from
O	507	508	a
O	509	515	subset
O	516	518	of
O	519	525	TARGIT
O	525	526	-
O	526	527	A
O	528	540	participants
O	541	544	who
O	545	553	received
O	554	560	TARGIT
O	560	561	-
O	561	565	IORT
O	566	568	as
O	569	570	a
O	571	579	separate
O	580	589	procedure
O	590	591	(
O	591	604	postpathology
O	604	605	)
O	605	606	.

O	607	615	Patients
O	616	625	completed
O	626	627	a
O	628	636	cosmetic
O	637	647	assessment
O	648	654	before
O	655	664	radiation
O	665	672	therapy
O	673	676	and
O	677	685	annually
O	686	696	thereafter
O	697	700	for
O	701	703	at
O	704	709	least
O	710	711	5
O	712	717	years
O	717	718	.

O	719	727	Patients
O	728	732	also
O	733	742	completed
O	743	746	the
O	747	755	combined
O	756	764	European
O	765	777	Organization
O	778	781	for
O	782	790	Research
O	791	794	and
O	795	804	Treatment
O	805	807	of
O	808	814	Cancer
O	815	816	(
O	816	821	EORTC
O	821	822	)
O	823	827	core
O	828	841	questionnaire
O	842	845	and
O	846	852	Breast
O	852	853	-
O	853	861	Specific
O	862	868	Module
O	869	871	in
O	872	880	addition
O	881	883	to
O	884	887	the
O	888	892	Body
O	893	898	Image
O	899	904	after
O	905	911	Breast
O	912	918	Cancer
O	919	932	Questionnaire
O	933	935	at
O	936	944	baseline
O	945	948	and
O	949	957	annually
O	958	968	thereafter
O	968	969	.

O	970	973	The
O	974	982	combined
O	983	988	EORTC
O	989	1003	questionnaires
O	1004	1008	were
O	1009	1013	also
O	1014	1023	collected
O	1024	1025	3
O	1025	1026	,
O	1027	1028	6
O	1028	1029	,
O	1030	1033	and
O	1034	1035	9
O	1036	1042	months
O	1043	1048	after
O	1049	1053	wide
O	1054	1059	local
O	1060	1068	excision
O	1068	1069	.

O	1070	1072	An
B-outcome	1073	1082	Excellent
I-outcome	1082	1083	-
I-outcome	1083	1087	Good
I-outcome	1088	1096	cosmetic
I-outcome	1097	1103	result
O	1104	1107	was
O	1108	1114	scored
O	1115	1119	more
O	1120	1125	often
O	1126	1130	than
O	1131	1132	a
O	1133	1137	Fair
O	1137	1138	-
O	1138	1142	Poor
O	1143	1149	result
O	1150	1153	for
O	1154	1158	both
O	1159	1168	treatment
O	1169	1175	groups
O	1176	1182	across
O	1183	1186	all
O	1187	1191	time
O	1192	1198	points
O	1198	1199	.

O	1200	1203	The
O	1204	1210	TARGIT
O	1210	1211	-
O	1211	1215	IORT
O	1216	1224	patients
O	1225	1233	reported
B-outcome	1234	1240	better
I-outcome	1241	1247	breast
I-outcome	1247	1248	-
I-outcome	1248	1255	related
I-outcome	1256	1259	QOL
O	1260	1264	than
O	1265	1269	EBRT
O	1270	1278	patients
O	1278	1279	.

B-outcome	1280	1293	Statistically
I-outcome	1294	1297	and
I-outcome	1298	1308	clinically
I-outcome	1309	1320	significant
I-outcome	1321	1332	differences
O	1333	1337	were
O	1338	1342	seen
O	1343	1345	at
O	1346	1351	month
O	1352	1353	6
O	1354	1357	and
O	1358	1362	year
O	1363	1364	1
O	1364	1365	,
O	1366	1370	with
O	1371	1375	EBRT
O	1376	1384	patients
O	1385	1391	having
O	1392	1402	moderately
O	1403	1408	worse
O	1409	1415	breast
O	1416	1424	symptoms
O	1425	1426	(
O	1426	1427	a
O	1428	1441	statistically
O	1442	1453	significant
O	1454	1464	difference
O	1465	1467	of
O	1468	1472	more
O	1473	1477	than
O	1478	1480	10
O	1481	1483	in
O	1484	1485	a
O	1486	1489	100
O	1489	1490	-
O	1490	1495	point
O	1496	1501	scale
O	1501	1502	)
O	1503	1507	than
O	1508	1514	TARGIT
O	1514	1515	-
O	1515	1519	IORT
O	1520	1528	patients
O	1529	1531	at
O	1532	1537	these
O	1538	1542	time
O	1543	1549	points
O	1549	1550	.

O	1551	1559	Patients
O	1560	1567	treated
O	1568	1572	with
O	1573	1579	TARGIT
O	1579	1580	-
O	1580	1584	IORT
O	1585	1587	on
O	1588	1591	the
O	1592	1598	TARGIT
O	1598	1599	-
O	1599	1600	A
O	1601	1606	trial
O	1607	1611	have
O	1612	1619	similar
O	1620	1624	self
O	1624	1625	-
O	1625	1633	reported
O	1634	1642	cosmetic
O	1643	1650	outcome
O	1651	1654	but
O	1655	1661	better
O	1662	1668	breast
O	1668	1669	-
O	1669	1676	related
O	1677	1680	QOL
O	1681	1689	outcomes
O	1690	1694	than
O	1695	1703	patients
O	1704	1711	treated
O	1712	1716	with
O	1717	1721	EBRT
O	1721	1722	.

O	1723	1727	This
O	1728	1737	important
O	1738	1746	evidence
O	1747	1750	can
O	1751	1761	facilitate
O	1762	1765	the
O	1766	1775	treatment
O	1776	1784	decision
O	1784	1785	-
O	1785	1791	making
O	1792	1799	process
O	1800	1803	for
O	1804	1812	patients
O	1813	1816	who
O	1817	1821	have
O	1822	1827	early
O	1828	1834	breast
O	1835	1841	cancer
O	1842	1850	suitable
O	1851	1854	for
O	1855	1861	breast
O	1861	1862	-
O	1862	1872	conserving
O	1873	1880	surgery
O	1881	1884	and
O	1885	1891	inform
O	1892	1897	their
O	1898	1908	clinicians
O	1908	1909	.
